Taranabant, a novel cannabinoid type 1 receptor inverse agonist.

Abstract

Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.

• Authors: Bradley A Fremming, Steven T Boyd
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 10 Pg. 1116-29 (Oct 2008) ISSN: 1472-4472 [Print] England
• PMID: 18821475 (Publication Type: Journal Article, Review)

Chemical References

• Amides
• Anti-Obesity Agents
• Pyridines
• Receptor, Cannabinoid, CB1
• N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide

Topics

• Amides (adverse effects, pharmacokinetics, therapeutic use)
• Animals
• Anti-Obesity Agents (adverse effects, pharmacokinetics, therapeutic use)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Contraindications
• Drug Industry
• Humans
• Obesity (drug therapy)
• Patents as Topic
• Pyridines (adverse effects, pharmacokinetics, therapeutic use)
• Receptor, Cannabinoid, CB1 (agonists)
• Structure-Activity Relationship
• Tobacco Use Disorder (drug therapy)